NASDAQ: CGONCg Oncology Inc Stock
$40.94-0.67 (-1.61%)
Updated Dec 12, 2025
CGON Price
$40.94
Fair Value Price
$3.85
Market Cap
$3.30B
52 Week Low
$14.80
52 Week High
$46.01
P/E
-20.07x
P/B
4.8x
P/S
1,421.81x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.17M
Earnings
-$151.48M
Gross Margin
27.5%
Operating Margin
-6,967.99%
Profit Margin
-6,968%
Debt to Equity
0.06
Operating Cash Flow
-$117M
Beta
1.54
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CGON Overview
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CGON's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CGON
Ranked#91 of 487
Ranked#91 of 487
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $319.06 | A | |
| $15.85 | A | |
| $20.63 | A |
Be the first to know about important CGON news, forecast changes, insider trades & much more!
CGON News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CGON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CGON ($40.94) is overvalued by 964.23% relative to our estimate of its Fair Value price of $3.85 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CGON ($40.94) is not significantly undervalued (964.23%) relative to our estimate of its Fair Value price of $3.85 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CGON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CGON due diligence checks available for Premium users.
Valuation
CGON fair value
Fair Value of CGON stock based on Discounted Cash Flow (DCF)
Price
$40.94
Fair Value
$3.85
Overvalued by
964.23%
CGON ($40.94) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CGON ($40.94) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CGON is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CGON price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-20.07x
Industry
155.66x
Market
44.99x
CGON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.8x
Industry
5.32x
CGON is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CGON's financial health
Profit margin
Revenue
$1.7M
Net Income
-$43.8M
Profit Margin
-2,629.5%
CGON's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CGON's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$729.9M
Liabilities
$42.3M
Debt to equity
0.06
CGON's short-term assets ($695.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CGON's short-term assets ($695.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CGON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$38.9M
Investing
$15.0M
Financing
$54.4M
CGON's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CGON vs Biotech Stocks
Cg Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.